Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02581345 | Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis | PHASE3 | COMPLETED | 572 | — | — | Sep 1, 2015 | Apr 1, 2017 | Oct 16, 2018 | - | — |
| Name | Type | Description |
|---|---|---|
| M923 | BIOLOGICAL | Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α) |
| Humira | BIOLOGICAL | Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α) |